Search Results
Sep 07, 2026, 05:42 ET Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
trajectories. Mechanistically, the drug acted as a senomorphic agent, suppressing key drivers of cellular senescence, including EREG, ESM1, IGFBP4, ITGA2, MMP10, MMP13, and SPP1 while downregulating growth-factor signaling pathways associated with accelerated aging, including RTK–PI3K and RAS–ERK,
More news about: Insilico Medicine
Aug 13, 2026, 08:15 ET Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target, the mitochondrial membrane potential (MMP), also called the "Δψm". These two mechanisms include (1) the return of the efficiency of mitochondrial. Merger-associated financings are expected to
More news about: Pulmatrix Inc.
Aug 04, 2026, 08:00 ET Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
BOTOX® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX® Cosmetic would become the first and only neurotoxin indicated
More news about: AbbVie
Jul 28, 2026, 06:00 ET CENTENE CORPORATION REPORTS SECOND QUARTER 2026 RESULTS
Aged, Blind, or Disabled (ABD), Intellectual and Developmental Disabilities (IDD), Long-Term Services and Supports (LTSS), and Medicare-Medicaid Plans (MMP) Duals. The Company operated MMPs through December 31, 2025. In 2026 these members are included in Medicare as a result of the Centers for Medicare and
More news about: Centene Corporation
Jul 22, 2026, 09:21 ET Massachusetts Mobile Integrated Health Provider Releases 2025 Results Across Medicare Advantage, Medicaid, and Dual-Eligible Populations
longitudinal care teams.In 2025, instED completed more than 12,500 encounters with over 5,500 unique patients enrolled in Medicare Advantage, MMP, FIDE-SNP, PACE, and Medicaid plans. Nearly seventy percent of requests came directly from patients, alongside 471 unique referring providers and hundreds
More news about: instED
Jul 09, 2026, 05:30 ET Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty
including cardiac sarcoidosis. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, has completed a Phase 1 study in healthy volunteers, with development targeted in severe asthma and COPD. In January 2026, the global rights for the MMP-12 Inhibitor series were exclusively licensed to Primevera Therapeutics
More news about: Foresee Pharmaceuticals Co., Ltd.
Jun 16, 2026, 08:30 ET New Study Reveals 432% Return On Investment for Retailers and Partners using Button's Patented AI-powered Mobile Routing Technology
mobile links and routing shoppers to their intended product pages, all while prioritizing the in-app experience. Delivering Growth on Top of MMP DeeplinksThis study accounted for participants' use of mobile measurement platforms (MMPs), which report on channel performance but do not
More news about: BUTTON
Jun 08, 2026, 08:00 ET Vasa Therapeutics to Deliver Two Presentations on VS-041 at ECM2026, Featuring Preclinical and First-in-Human Data and Ongoing Phase 1c Trial Design in HFpEF
trial.Presentation Details: Oral Presentation: Title: Preclinical Efficacy and Phase 1 Safety and Tolerability of VS-041: A Novel MMP Inhibitor for the Treatment of HFpEF Presenter: Noreen R. Henig, MDDate & Time: Tuesday, June 16, 2026, 14:00–15:00
More news about: Vasa Therapeutics
Jun 08, 2026, 05:00 ET Foresee's Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2a Platform Trial
including cardiac sarcoidosis. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, has completed a Phase 1 study in healthy volunteers, with development targeted in severe asthma and COPD. In January 2026, the global rights for the MMP-12 Inhibitor series were exclusively licensed to Primevera Therapeutics
More news about: Foresee Pharmaceuticals Co., Ltd.
May 27, 2026, 04:43 ET Foresee Pharmaceuticals Announces Completion of Casppian Phase 3 Study with Last Patient Last Visit and Confirms Topline Results: 94% of Patients Achieve LH Suppression with 6-Month Dosing Interval of Leuprolide Mesylate, also the acceptance of Casppian Study for Presentation at Endocrine Society, ENDO 2026 Medical Conference, as a Potential New Six-Month Treatment Option for Central Precocious Puberty
including cardiac sarcoidosis. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, has completed a Phase 1 study in healthy volunteers, with development targeted in severe asthma and COPD. In January 2026, the global rights for the MMP-12 Inhibitor series were exclusively licensed to Primevera Therapeutics
More news about: Foresee Pharmaceuticals Co., Ltd.
May 18, 2026, 08:00 ET Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
TNF-α results in reductions in C-reactive protein (CRP), Interleukin 6 (IL-6), Intercellular Adhesion Molecule 1 (ICAM-1), Matrix Metalloproteinase 3 (MMP-3), and Vascular Endothelial Growth Factor (VEGF), all inflammatory markers. Bio-Thera signed an exclusive commercialization agreement with Intas
More news about: Bio-Thera Solutions, Ltd
May 15, 2026, 08:20 ET Pulmatrix Announces First Quarter 2026 Financial Results
ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target, the mitochondrial membrane potential (MMP), also called the "Δψm". These two mechanisms include (1) the return of the efficiency of mitochondrial function in aging cells almost immediately back
More news about: Pulmatrix Inc.
Apr 28, 2026, 06:00 ET CENTENE CORPORATION REPORTS FIRST QUARTER 2026 RESULTS
Aged, Blind, or Disabled (ABD), Intellectual and Developmental Disabilities (IDD), Long-Term Services and Supports (LTSS), and Medicare-Medicaid Plans (MMP) Duals. The Company operated MMPs through December 31, 2025. In 2026 these members are included in Medicare as a result of the Centers for Medicare and
More news about: Centene Corporation
Apr 21, 2026, 08:00 ET Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target, the mitochondrial membrane potential (MMP), also called the "Δψm". These two mechanisms include (1) the return of the efficiency of mitochondrial function in aging cells almost immediately back
More news about: Pulmatrix Inc.
Mar 26, 2026, 08:00 ET Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target, the mitochondrial membrane potential (MMP), also called the "Δψm". These two mechanisms include (1) the return of the efficiency of mitochondrial function in aging cells almost immediately back
More news about: Pulmatrix Inc.
Mar 25, 2026, 09:00 ET PDW Raises Over $110M in Series B Financing to Expand Product Offerings, Strengthen Engineering Capabilities and Scale Production of Modular Military Drones
environments, including the C100 quadcopter, the Attritable Munition strike drone, SIM flight simulator, CORE mission planning software, Multi-Mission Payloads (MMP), Range Extension Kit, and an anti-jam radio.Houlihan Lokey served as exclusive financial advisor to PDW on this landmark defense technology transaction.About
More news about: PDW
Mar 23, 2026, 07:46 ET Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in India
TNF- results in reductions in C-reactive protein (CRP), Interleukin 6 (IL-6), Intercellular Adhesion Molecule 1 (ICAM-1), Matrix Metalloproteinase 3 (MMP-3), and Vascular Endothelial Growth Factor (VEGF), all inflammatory markers. The reference medicine golimumab has been approved in the Canada for several
More news about: Bio-Thera Solutions, Ltd
Mar 06, 2026, 04:20 ET Foresee Pharmaceuticals Welcomes Positive CHMP Opinion Recommending Approval of CAMCEVI 21mg, 3-month strength in the European Union for Advanced Prostate Cancer
sarcoidosis. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, has completed a Phase 1 study in healthy volunteers, with development targeted in severe asthma and COPD. In January 2026, Foresee has licensed exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics,
More news about: Foresee Pharmaceuticals Co., Ltd.
Feb 13, 2026, 06:08 ET STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
TNF-α results in reductions in C-reactive protein (CRP), Interleukin 6 (IL-6), Intercellular Adhesion Molecule 1 (ICAM-1), Matrix Metalloproteinase 3 (MMP-3), and Vascular Endothelial Growth Factor (VEGF), all inflammatory markers. Gotenfia® has been approved in Europe for several indications
More news about: Bio-Thera Solutions, Ltd
Feb 12, 2026, 09:00 ET Devonian reports additional molecular data from MASH liver study
to placebo-treated animals.Fibrosis-related genes significantly modulated by Thykamine™ included CCN1, CCN2, COL1A1, COL1A2, COL5A2, JAG1, MMP2, MMP13, SERPINE1, SERPINE2, SNAI1, and TGFBR1, supporting the previously observed decreases in collagen deposition, α-SMA expression and fibrosis progression.Thykamine™
More news about: Devonian Health Group Inc.
Feb 10, 2026, 09:00 ET DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
chemokines Ccl2 and Cxcl2 (inflammatory cell recruitment). In parallel, Thykamine™ significantly increased Mmp9, a matrix metalloproteinase associated with extracellular matrix turnover, while reducing Mmp13, a collagenase often linked to progressive tissue injury and inflammation. Together, this gene expression
More news about: Devonian Health Group Inc.
Feb 06, 2026, 06:00 ET CENTENE CORPORATION REPORTS 2025 RESULTS AND ANNOUNCES 2026 GUIDANCE
Aged, Blind, or Disabled (ABD), Intellectual and Developmental Disabilities (IDD), Long-Term Services and Supports (LTSS) and Medicare-Medicaid Plans (MMP) Duals.(3)
More news about: Centene Corporation
Feb 04, 2026, 05:02 ET Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP)
sarcoidosis. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, has completed a Phase 1 study in healthy volunteers, with development targeted in severe asthma and COPD. In January 2026, Foresee has licensed exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics,
More news about: Foresee Pharmaceuticals Co., Ltd.
Jan 08, 2026, 04:01 ET Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
global licensing agreement with Primevera Therapeutics, LLC (hereinafter referred to as "Primevera") for its MMP-12 inhibitor programs. The agreement includes FP-025, FP-020 and third-generation MMP-12 inhibitors currently in the drug discovery stage. In return, Foresee USA will receive an upfront
More news about: Foresee Pharmaceuticals Co., Ltd.
Jan 08, 2026, 03:42 ET Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
global licensing agreement with Primevera Therapeutics, LLC (hereinafter referred to as "Primevera") for its MMP-12 inhibitor programs. The agreement includes FP-025, FP-020 and third-generation MMP-12 inhibitors currently in the drug discovery stage. In return, Foresee USA will receive an upfront
More news about: Foresee Pharmaceuticals Co., Ltd.